Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin

Journal of Rheumatology

Volumn 38, Issue 3, 2011, Pages 485-491

  Choe, Jung Yoon ^a   Lee, Geon Ho ^a   Kim, Seong Kyu ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Gout; Interleukin 1 ; Interleukin 6; Osteoprotegerin; Radiographic damage; RANKL; Soluble interleukin 6 receptor

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOLUBLE INTERLEUKIN 6 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE EROSION; BONE INJURY; BONE RADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GOUT; HUMAN; IMAGE DISPLAY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

ADULT; BONE AND BONES; CHRONIC DISEASE; GOUT; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RANK LIGAND; RECEPTORS, INTERLEUKIN-6;

EID: 79952370587     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100727     Document Type: Article

References (26)

1. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003;349:1647-55.
2. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004;50:2400-14.
3. Perez-Ruiz F, Dalbeth N, Urresola A, de Miguel E, Schlesinger N. Imaging of gout: findings and utility. Arthritis Res Ther 2009;11:232.
4. Bouchard L, de Médicis R, Lussier A, Naccache PH, Poubelle PE. Inflammatory microcrystals alter the functional phenotype of human osteoblast-like cells in vitro: synergism with IL-1 to overexpress cyclooxygenase-2. J Immunol 2002;168:5310-7. (Pubitemid 34498306)
5. Dalbeth N, Smith T, Nicolson B, Clark B, Callon K, Naot D, et al. Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum 2008;58:1854-65. (Pubitemid 351847541)
6. Di Giovine FS, Malawista SE, Nuki G, Duff GW. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 1987;138:3213-18. (Pubitemid 17071894)
7. Chen CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006;116:2262-71. (Pubitemid 44162336)
8. Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E, van der Ven J, Kullberg BJ, Netea MG, et al. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process. Ann Rheum Dis 2009;68:273-8.
9. Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 1997;24:1510-6. (Pubitemid 27320690)
10. Tsai PC, Chen CJ, Lai HM, Chang SJ. Analysis of polymorphisms in the promoter region and protein levels of interleukin-6 gene among gout patients. Clin Exp Rheumatol 2008;26:841-7.
11. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999;247:84-93. (Pubitemid 29393964)
12. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924-8. (Pubitemid 24008752)
13. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
14. Dalbeth N, Clark B, McQueen F, Doyle A, Taylor W. Validation of a radiographic damage index in chronic gout. Arthritis Rheum 2007;57:1067-73. (Pubitemid 47237335)
15. Nguyen C, Ea H-K, Palazzo E, Lioté F. Tophaceous gout: an unusual cause of multiple fractures. Scand J Rheumatol 2010;39:93-6.
16. Alwan WH, Dieppe PA, Elson CJ, Bradfield JW. Hydroxyapatite and urate crystal induced cytokine release by macrophages. Ann Rheum Dis 1989;48:476-82. (Pubitemid 19158935)
17. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006;8 Suppl 2:S3.
18. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60. (Pubitemid 34856121)
19. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6.
20. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006;8 Suppl 1:S2.
21. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000;27:1501-5. (Pubitemid 30354052)
22. Bloch C, Hermann G, Yu TF. A radiologic reevaluation of gout: a study of 2,000 patients. AJR Am J Roentgenol 1980;134:781-7. (Pubitemid 10095908)
23. Dalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis 2009;68:1290-5.
24. Roseff R, Wohlgethan JR, Sipe JD, Canoso JJ. The acute phase response in gout. J Rheumatol 1987;14:974-7.
25. Andracco R, Zampogna G, Parodi M, Cimmino MA. Risk factors for gouty dactylitis. Clin Exp Rheumatol 2009;27:993-5.
26. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008;67:769-74. (Pubitemid 351829376)